Document is current
Any future updates will be listed below
-
Authors
Garcia-Gimenez, Alicia
Ditcham, Jonathan E. https://orcid.org/0009-0001-1909-9499
Azazi, Dhoyazan M. A. https://orcid.org/0000-0001-9085-4031
Giotopoulos, George https://orcid.org/0000-0003-1390-6592
Asby, Ryan
Meduri, Eshwar
Bagri, Jaana
Sakakini, Nathalie
Lopez, Cecile K.
Narayan, Nisha https://orcid.org/0000-0002-4106-2166
Beinortas, Tumas
Agrawal-Singh, Shuchi
Fung, Kent
O’Connor, David
Mansour, Marc R. https://orcid.org/0000-0001-6835-3791
Alabed, Husam B. R.
Jenkins, Benjamin https://orcid.org/0000-0003-0038-9709
Koulman, Albert https://orcid.org/0000-0001-9998-051X
Murphy, Michael P. https://orcid.org/0000-0003-1115-9618
Horton, Sarah J. https://orcid.org/0000-0001-8418-5783
Huntly, Brian J. P. https://orcid.org/0000-0003-0312-161X
Richardson, Simon E. https://orcid.org/0000-0003-4343-4784
-
Funding
Funding for this research was provided by:
Cancer Research UK (C67279/A27957)
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 24 April 2025
First Online: 20 May 2025
Competing interests
: N.N. is a former employee of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to Venetoclax. N.N. received payments from WEHI related to Venetoclax. The combination of BCL2 and CREBBP/EP300 inhibitors in ALL is protected under Cambridge Enterprise patent PCT/GB2024/052398 (S.E.R. and B.P.J.H. listed inventors). The remaining authors declare no competing interests.
